Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

430 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Single tablet regimen with abacavir/lamivudine/dolutegravir compared with two-drug regimen with lamivudine and dolutegravir as different strategies of simplification from a multicenter HIV cohort study.
Baldin G, Ciccullo A, Rusconi S, Madeddu G, Sterrantino G, Freedman A, Giacometti A, Celani L, Latini A, Rossetti B, Cossu MV, Giacomelli A, Lagi F, Capetti A, Di Giambenedetto S. Baldin G, et al. Among authors: latini a. Infez Med. 2019 Dec 1;27(4):410-414. Infez Med. 2019. PMID: 31846991 Free article.
The Less Drugs Regimens (LDRs) therapy approach in HIV-1: an Italian expert panel perspective for the long-term management of HIV-1 infection.
Scientific Coordination Committee; Marcotullio S, Andreoni M, Antinori A, d'Arminio Monforte A, Di Perri G, Galli M, Ippolito G, Perno CF, Rizzardini G, Lazzarin A; Rapporteur Committee; Cinque P, Fares G, Foglia E, Gervasoni C, Murri R, Nozza S, Rusconi S. Scientific Coordination Committee, et al. New Microbiol. 2012 Jul;35(3):259-77. Epub 2012 Jun 30. New Microbiol. 2012. PMID: 22842596 Free article. No abstract available.
Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter analysis.
Zaccarelli M, Fabbiani M, Pinnetti C, Borghi V, Giannetti A, Sterrantino G, Lorenzini P, Latini A, Loiacono L, Colafigli M, Ammassari A, D'Ettorre G, Plazzi M, Di Giambenedetto S, Antinori A. Zaccarelli M, et al. Among authors: latini a. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19802. doi: 10.7448/IAS.17.4.19802. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25397546 Free PMC article.
Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial.
Fabbiani M, Di Giambenedetto S, Quiros-Roldan E, Latini A, Vullo V, Antinori A, Castagna A, Orofino G, Francisci D, Grilli E, Madeddu G, Grima P, Rusconi S, Del Pin B, Mondi A, Borghetti A, Focà E, Colafigli M, De Luca A, Cauda R. Fabbiani M, et al. Among authors: latini a. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19808. doi: 10.7448/IAS.17.4.19808. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25397552 Free PMC article.
Simplification to co-formulated rilpivirine/emtricitabine/tenofovir in virologically suppressed patients: Data from a multicenter cohort.
Pinnetti C, Di Giambenedetto S, Maggiolo F, Lorenzini P, Fabbiani M, Tommasi C, Latini A, Ammassari A, Loiacono L, Sterrantino G, Bellagamba R, Boumis E, Antinori A, Zaccarelli M. Pinnetti C, et al. Among authors: latini a. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19812. doi: 10.7448/IAS.17.4.19812. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25397556 Free PMC article.
Switching to Coformulated Rilpivirine/Emtricitabine/Tenofovir in Virologically Suppressed Patients: Data From a Multicenter Cohort.
Pinnetti C, Di Giambenedetto S, Maggiolo F, Fabbiani M, Sterrantino G, Latini A, Lorenzini P, Ammassari A, Loiacono L, Bellagamba R, Boumis E, Cauda R, Antinori A, Zaccarelli M. Pinnetti C, et al. Among authors: latini a. J Acquir Immune Defic Syndr. 2015 Dec 1;70(4):e147-50. doi: 10.1097/QAI.0000000000000727. J Acquir Immune Defic Syndr. 2015. PMID: 26090757 No abstract available.
Reduced risk of Efavirenz Discontinuation in Naïve Patients Starting First-Line Antiretroviral Therapy with Single Tablet versus dual Tablet Regimen.
Fabbiani M, Zaccarelli M, Latini A, Sterrantino G, D'Ettorre G, Grima P, Mondi A, Rossetti B, Borchi B, Giuliani M, Antinori A, De Luca A, Di Giambenedetto S. Fabbiani M, et al. Among authors: latini a. HIV Med. 2016 May;17(5):385-9. doi: 10.1111/hiv.12313. Epub 2015 Sep 22. HIV Med. 2016. PMID: 26394902 Free article.
Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter observational study.
Latini A, Fabbiani M, Borghi V, Sterrantino G, Giannetti A, Lorenzini P, Loiacono L, Ammassari A, Bellagamba R, Colafigli M, D'Ettorre G, Di Giambenedetto S, Antinori A, Zaccarelli M. Latini A, et al. BMC Infect Dis. 2016 Aug 11;16(1):401. doi: 10.1186/s12879-016-1703-z. BMC Infect Dis. 2016. PMID: 27515949 Free PMC article.
Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus.
Puoti M, Lorenzini P, Cozzi-Lepri A, Gori A, Mastroianni C, Rizzardini G, Mazzarello G, Antinori A, d'Arminio Monforte A, Girardi E; Icona Foundation Study Group. Puoti M, et al. Clin Microbiol Infect. 2017 Apr;23(4):267.e1-267.e4. doi: 10.1016/j.cmi.2016.12.003. Epub 2016 Dec 9. Clin Microbiol Infect. 2017. PMID: 27956268 Free article.
Efficacy and tolerability of dolutegravir and two nucleos(t)ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients.
Borghetti A, Baldin G, Capetti A, Sterrantino G, Rusconi S, Latini A, Giacometti A, Madeddu G, Picarelli C, De Marco R, Cossu MV, Lagi F, Cauda R, De Luca A, Di Giambenedetto S; Odoacre Study Group. Borghetti A, et al. Among authors: latini a. AIDS. 2017 Jan 28;31(3):457-459. doi: 10.1097/QAD.0000000000001357. AIDS. 2017. PMID: 28079545 No abstract available.
430 results